A securities class action has been filed in the USDC — S.D.N.Y. against Regeneron Pharmaceuticals, Inc. (REGN) (“Regeneron ” or the “Company”), on behalf of all persons or entities who purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”).
Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others. One of the Company’s primary products is Eylea, an injection to treat age-related macular degeneration, among other conditions, by inhibiting anti-vascular endothelial growth factor (“anti-VEGF”). In November 2011, the U.S. Food and Drug Administration (“FDA”) approved Eylea as an anti-VEGF inhibitor for wet age-related macular degeneration, and in August 2023, the FDA approved Eylea HD, a high dose version of Eylea. The Company is “substantially dependent on the success of Eylea [and] Eylea HD.” Sales of the Company’s products, including Eylea and Eylea HD, are, in turn, largely dependent on the availability and extent of reimbursement from third-party payors, including programs such as Medicare and Medicaid.
The complaint alleges Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors:
(1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card;
(2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea;
(3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price;
(4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage;
(5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales;
(6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and
(7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis, thereby harming investors.
If you purchased Regeneron securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.